Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Videos
Diagnostics
In Vitro Diagnostics
Return to: MDBR Home | Diagnostics | In Vitro Diagnostics

Akers Biosciences signs three-year agreement with GNYHA Services for heparin PF4 rapid test

Published 23 December 2016

Akers Biosciences, a developer of rapid health information technologies, reported that it has signed a three-year agreement with the Greater New York Hospital Association (GNYHA) to introduce the company's flagship rapid tests for heparin-induced thrombocytopenia across GNYHA's network of over 300 member hospitals and health systems.

 In fact, the entity with which the Company has entered into an agreement is GNHYA Services, a group purchasing organization affiliated with GNYHA.

Akers Bio looks forward to working with GNYHA Services to introduce PIFA Heparin/PF4 clinical diagnostic products that will improve effectiveness, operational efficiency and profitable outcomes for their members.

Akers Bio develops, manufactures, and supplies rapid screening and testing products designed to deliver quicker and more cost-effective healthcare information to healthcare providers and consumers.

The Company has advanced the science of diagnostics while responding to major shifts in healthcare through the development of several proprietary platform technologies. The Company's state-of-the-art rapid diagnostic assays can be performed virtually anywhere in minutes when time is of the essence.

The Company has aligned with major healthcare companies and high volume medical product distributors to maximize product offerings, and to be a major worldwide competitor in diagnostics.



Source: Company Press Release